Editorial: Metabolic reprogramming for acquiring therapeutic resistance in glioblastoma

Tsung I. Hsu

doi:10.3389/fonc.2023.1220063

Editorial: Metabolic reprogramming for acquiring therapeutic resistance in glioblastoma

研究成果: 雜誌貢獻 › 社論 › 同行評審

原文	英語
文章編號	1220063
期刊	Frontiers in Oncology
卷	13
DOIs	https://doi.org/10.3389/fonc.2023.1220063
出版狀態	已發佈 - 2023

ASJC Scopus subject areas

腫瘤科
癌症研究

UN SDG

此研究成果有助於以下永續發展目標

存取文件

10.3389/fonc.2023.1220063

其它文件與鏈接

引用此

@article{65fe101d19124c6289da95a787743f5d,

title = "Editorial: Metabolic reprogramming for acquiring therapeutic resistance in glioblastoma",

keywords = "flavins, glioblastoma, mass spectrometry, metabolic reprogramming, orexin A, succinylation, temozolomide, therapeutic resistance",

author = "Hsu, {Tsung I.}",

year = "2023",

doi = "10.3389/fonc.2023.1220063",

language = "English",

volume = "13",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Editorial

T2 - Metabolic reprogramming for acquiring therapeutic resistance in glioblastoma

AU - Hsu, Tsung I.

PY - 2023

Y1 - 2023

KW - flavins

KW - glioblastoma

KW - mass spectrometry

KW - metabolic reprogramming

KW - orexin A

KW - succinylation

KW - temozolomide

KW - therapeutic resistance

UR - http://www.scopus.com/inward/record.url?scp=85166470440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85166470440&partnerID=8YFLogxK

U2 - 10.3389/fonc.2023.1220063

DO - 10.3389/fonc.2023.1220063

M3 - Editorial

AN - SCOPUS:85166470440

SN - 2234-943X

VL - 13

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 1220063

ER -